Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

IBM Enters The Amazing P53 Race

|Includes: Cellceutix Corp. (CTIX), GSK, IBM, PFE

IBM Is Now Positioned For Major Biotech (P53) Discovery

Obviously part of my title has been borrowed from a most noteworthy Seeking Alpha author. I begin by quoting extensively with four paragraphs from an article written by Hal Hodson of NewScientist Tech and published on August 27th, 2014. I encourage all to follow the IBM hyperlink to this informative article and to express gratitude to both the author and publisher. My discussion following the long quote, will be more as an informed clairvoyant, with hopefully a disciplined but open ended scientific imagination. Critical and creative comments are coveted. It is very possible that an analytical comment could be far more valuable than anything that I contribute, other than the catalyst to present.

IBM & Baylor University Enter The Amazing P53 Race.

"IN MAY last year, a supercomputer in San Jose, California, read 100,000 research papers in 2 hours. It found completely new biology hidden in the data. Called KnIT, the computer is one of a handful of systems pushing back the frontiers of knowledge without human help...

KnIT didn't read the papers like a scientist - that would have taken a lifetime. Instead, it scanned for information on a protein called p53, and a class of enzymes that can interact with it, called kinases. Also known as "the guardian of the genome", p53 suppresses tumors in humans. KnIT trawled the literature searching for links that imply undiscovered p53 kinases, which could provide routes to new cancer drugs.

Having analyzed papers up until 2003, KnIT identified seven of the nine kinases discovered over the subsequent 10 years. More importantly, it also found what appeared to be two p53 kinases unknown to science. Initial lab tests confirmed the findings, although the team wants to repeat the experiment to be sure.

KnIT is a collaboration between IBM and Baylor College of Medicine in Houston, Texas. It is the latest step into a weird world where autonomous machines make discoveries that are beyond scientists, simply by rifling more thoroughly through what we already know, and faster than any human can."... Later in the article below.

The purpose of data mining can also be flipped. Instead of finding new insights into specialized topics, systems like KnIT can find holes in existing research that need to be plugged.

Beth Israel and Pfizer Appear Validated By The IBM, Baylor Entrance

When the risk taking entrepreneurial minds at Beth Israel encountered pre-clinical Kevetrin, it is apparent that the first primary vision that they had for Kevetrin, as a very safe P53 activating compound was to unite it with two of Pfizer's (NYSE:PFE) multi-kinase inhibitors. After the first round of pre-clinical trials it appears as though it was very successful, results were obtained in tumor shrinkage and tumor regression which were never accomplished prior to the pre-clinical. Pfizer's (NYSE:PFE) Sutent, which appeared to be challenged by Glaxo Smith Kline's Votrient (NYSE:GSK) multi-kinase inhibitor, emerged with an angle in conjugation with Kevetrin, to perhaps thwart any competition. The point herein is Beth Israel and Dana Farber are validated in proving that their early sense of one of Kevetrin's primary potentials is bang on. This same sense has been conveyed by Cellceutix shareholders on I HUB. However, unfortunately some believe that this will be the primary domain of Kevetrin and that it will not achieve a mega-blockbuster status as a stand alone oncolytic compound. I strongly disagree with this position.

The overarching expanding reality that new kinase pathways have been and might be discovered reveal that Kevetrin's potential to accompany other existing or new multi-kinase inhibitors is a primary consideration for the Cellcetuix (OTCMKTS:CTIX) shareholder family. As the number of kinases has grown from 7 to 9, With Big Blue and Baylor working together, the number of kinases has grown from 7 to 9. A compound that can replicate in humans, similar to that which was achieved by Kevetrin and Sutent at Beth Israel in all 9 kinases, is all by itself a Mega-Blockbuster. As Kevetrin will soon arrive at MTD, the potential to analyze and determine if Kevetrin positively effects all 9 of the current kinase pathways is possible. Imagine a meeting between key executives from Cellceutix, Dana Farber, Beth Israel, MD Anderson, IMB and Baylor. Imagine if Big Blue decides that it wants to actually ride in the number one car in the P53 race instead of profoundly crunching the data.

Although in the gradual dose escalation studies of FDA 1, Kevetrin may indeed be revealing itself primarily as a companion to multi-kinase inhibitors for stage four and beyond patients. Once Kevetrin begins at MTD, working in stage 1, 2 and 3 cancer patients, I believe that its stand alone possibilities will become much more evident.

Summary The Potential Of Kevetrin Has Grown: The Time To Wait Has Shrunk.

All of the prior should earn me a "We hold these facts to be self evident" award. So where is the deeper, broader, higher meaning? As many of you reading this know Kevetrin's patent contains the possibilities of 30,000 different compounds. This numeric potential combined with the possibilities address various diseases was for some of us more of an obfuscation, as over a clarification. However, with the event of the IBM (NYSE:IBM) Baylor Supercomputer, we can see how the data P53, P21 and MDM2 can be simultaneously parsed and synthesized to produce major matches between Kevetrin and many diseases and maladies. Work that would have taken five years or more might be reduced to a few months and even weeks. As a result of the proceeding I have to state that every past valuation of Cellceutix, that I have made needs substantial upward revision. I actually regret this because I am not confident that anybody is going to pay anywhere near what Cellceutix is worth. If taken out, part of the offer will have to be in the shares of the acquiring company, so that we can experience another massive lift off once the CTIX acquisition is absorbed. That is my opinion!

A Few Words On HIV AIDs Kevetrin, Prurisol and Brilacidin

I have heard my fellow shareholders ask questions like this "Does Prurisol apply to HIV Aids", my answer is that it is possible that it could be part of a cocktail, I doubt much more. However, there is distinct data on P53 and HIV Aids. I believe that Kevetrin could help the immune system of HIV Aids victims in general. Also, I believe that HIV Aids related cancer could well be P53 related, which means that Kevetrin could both treat Aids related cancer and could also be of prophylactic value to HIV patients, who have not yet developed Cancer. Brilacidin also seems to have substantial application to HIV Aids bacteriological infection issues.

Where do Steve Jobs and IBM Intersect With P53?

Read this

Clark Kent or Louis Lane Will Write About Cellceutix Soon

Some analysts or major reporter will soon decide that to write about Cellceutix, will not require that they enter The Federal Witness Protection Program.

Yes, to buy shares in Cellceutix, is to risk 100% of ones principal and should only be considered by persons willing to accept that kind of risk.

Ella Ruth